Featured Article
Category: News
Peak IOP A Better Predictor Of Visual Field Progression Than Mean Pressure Or Fluctuation
IOP-dependent and IOP-independent risk factors affect visual field progression in patients treated for glaucoma, with peak IOP showing a stronger correlation than mean IOP or pressure fluctuation, a study found.
EyeMed Vision Care Adds Retinal Imaging Benefit In Support Of Eye Health And Vision Wellness
EyeMed Vision Care, one of the nation’s leading vision benefits companies and part of Luxottica (NYSE: LUX), a leader in vision care and eyewear, has begun offering retinal imaging as an optional benefit within a vision plan. Retinal imaging provides d…
Consumer Medication Information: One Page Fits All
Sandra Fryhofer, MD, talks about the new initiative for putting consumer drug information into a single document. Medscape Internal Medicine
Human Retina Protein Has The Molecular Capability To Function As A Light-Sensitive Magnetic Sensor
For migratory birds and sea turtles, the ability to sense the Earth’s magnetic field is crucial to navigating the long-distance voyages these animals undertake during migration. Humans, however, are widely assumed not to have an innate magnetic sense…
Poor Vision Leads To Falls For 270,000 Over-60s, UK
270,000 people in the UK aged 60+ who have fallen over in the last two years say that poor vision was a factor in their fall[i], according to new research released today to mark Age UK’s Falls Awareness Week 2011 (20-24 June). Many things can lead to …
Oxford BioMedica Announces Ocular Programme Update
Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment…
Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD
Oxford BioMedica plc, a leading gene therapy company, today announces that the first dose level of RetinoStat is safe and well-tolerated at one month following treatment.
‘A Sticky Situation’ – Part II
Featured Article
Long-Term Trends Confirm Safety Of Cataract Surgery
“Although there was considerable change in operative technique, this alone may not be the sole reason for the reduction in complications; other factors not measured in this study are likely involved,” the study authors said.
Recommendations on Cell Phone Use and Cancer Risk
Evidence is limited, but common-sense precautions can be taken until the science catches up with technology. Medscape Medical News
Yissum Presents A Virtual Cane For The Visually Impaired
Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, presented today at the Israeli Presidential Conference, a virtual cane that will significantly improve the orientation and mobility of sigh…
Preventive Care: Finally Covered, Says Don Berwick
Donald M. Berwick, MD, of CMS talks about what is now being covered for preventive care under the Affordable Care Act and where you can find more information. Government Perspectives on Healthcare
New Test To Screen For Glaucoma Damage
A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes. The technique, called short duration transient VEP (SD-tVEP), s…
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Difluprednate: A Novel Steroid for the Eye
Featured Article
FDA Plans to Extend Its Global Regulatory Reach
The FDA’s new strategy calls for it to evolve into a global agency that can work anywhere in the world. Medscape Medical News
Truly Portable Imager Produces Still And Video Images Of The Eye
Mentor, Ohio (June 16, 2011) – For convenient ocular imaging in any setting, Volk Optical’s new truly portable Pictor digital device enables ophthalmic imaging not possible with traditional fixed systems. The Pictor delivers high resolution images of t…